Press releases
- Novocure to Report Second Quarter 2024 Financial Results
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
More ▼
Key statistics
On Monday, Novocure Ltd (NVCRN:MEX) closed at 342.31, 24.30% above the 52 week low of 275.39 set on Oct 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 330.62 |
Average volume | 0.00 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.64m |
P/E (TTM) | -- |
Market cap | 2.06bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 20 minutes, as of Oct 02 2023 12:30 BST.
More ▼